Drug insight: Lycopene in the prevention and treatment of prostate cancer

Nature Clinical Practice Urology

Volumn 2, Issue 1, 2005, Pages 38-43

  Guns, Emma S ^a,b   Cowell, Simon P ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Department of Analytical Pharmacology   (United States)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Disease prevention; Lycopene; Prostate cancer; Treatment

Indexed keywords

ALPHA TOCOPHEROL; LYCOPEN; LYCOPENE; LYCORED; PLACEBO; SELENIUM;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; CANCER CELL; CANCER INCIDENCE; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CELL PROLIFERATION; CLINICAL TRIAL; CORRELATION ANALYSIS; DIET SUPPLEMENTATION; DISEASE MODEL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; ENDOCRINE SYSTEM; FOLLOW UP; HUMAN; NONHUMAN; NUTRITIONAL VALUE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK REDUCTION; TOMATO;

ANIMALS; ANTIOXIDANTS; CAROTENOIDS; CLINICAL TRIALS; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 20444504397     PISSN: 17434270     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpuro0073     Document Type: Review

References (52)

1. Di Mascio P et al. (1989) Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch Biochem Biophys 274: 532-538
2. Giovannucci E et al. (2002) A prospective study of tomato products, lycopene and prostate. J Natl Cancer Inst 94: 391-398
3. Rao AV (1999) Role of lycopene as antioxidant carotenoid in the prevention of chronic diseases: a review. Nutr Res 19: 305-323
4. Wertz K et al. (2004) Lycopene: modes of action to promote prostate health. Arch Biochem Biophys 430: 127-134
5. Gann PH et al. (1999) Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 59: 1225-1230
6. Giovannucci E et al. (1995) Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 87: 1767-1776
7. Bowen P et al. (2002) Tomato sauce supplementation and prostate cancer: lycopene accumulation and modulation of biomarkers of carcinogenesis. Exp Biol Mad (Maywood) 227: 886-893
8. Imaida K et al. (2001) Lack of chemopreventive effects of lycopene and curcumin on experimental rat prostate carcinogenesis. Carcinogenesis 22: 467-472
9. Guttenplan JB et al. (2001) Effects of a lycopene-rich diet on spontaneous and benzo[a]pyrene-induced mutagenesis in prostate, colon and lungs of the lacZ mouse. Cancer Lett 164: 1-6
10. Boileau TW et al. (2003) Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J Natl Cancer Inst 95: 1578-1586
11. Venkateswaran V et al. (2004) Antioxidants block prostate cancer in lady transgenic mice. Cancer Res 64: 5891-5896
12. Gann PH and Khachik F (2003) Tomatoes or lycopene versus prostate cancer: is evolution anti-reductionist? J Natl Cancer Inst 95: 1563-1565
13. Limpens J et al. (2004) Re: Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J Natl Cancer Inst 96: 554; author reply 554-555
14. Rao AV (1998) Bioavailability and in vivo antioxidant properties of lycopene from tomato products and their possible role in the prevention of cancer. Nutr Cancer 31: 199-203
15. Rao AV and Agarwal S (1999) Serum and tissue lycopene and biomarkers of oxidation in prostate cancer patients: a case-control study. Nutr Cancer 33: 159-164
16. Rao AV and Agarwal S (1998) Lycopene content of tomatoes and tomato products and their contribution to dietary lycopene. Food Res Intern 31: 737-741
17. Boileau AC et al. (1999) Cis-lycopene is more bioavailable than trans-lycopene in vitro and in vivo in lymph-cannulated ferrets. J Nutr 129: 1176-1181
18. Stahl W et al. (1992) cis-trans isomers of lycopene and beta-carotene in human serum and tissues. Arch Biochem Biophys 294: 173-177
19. Clinton SK et al. (1996) cis-trans lycopene isomers, carotenoids, and retinol in the human prostate. Cancer Epidemiol Biomarkers Prev 5: 823-833
20. Agarwal S and Rao AV (1998) Tomato lycopene and low density lipoprotein oxidation: a human dietary intervention study. Lipids 33: 981-984
21. Agarwal A et al. (2001) Lycopene content of tomato products: its stability, bioavailability and in vivo antioxidant properties. J Med Food 4: 9-15
22. Ferreira AL et al. (2000) Tissue distribution of lycopene in ferrets and rats after lycopene supplementation. J Nutr 130: 1256-1260
23. Zhao Z et al. (1998) Lycopene uptake and tissue disposition in male and female rats. Proc Soc Exp Biol Med 218: 109-114
24. Korytko PJ et al. (2003) Pharmacokinetics and tissue distribution of orally administered lycopene in male dogs. J Nutr 133: 2788-2792
25. Boileau TW et al. (2001) Testosterone and food restriction modulate hepatic lycopene isomer concentrations in male F344 rats. J Nutr 131: 1746-1752
26. Jain CK and Rao AV (1999) The effect of dietary lycopene on bioavailability, tissue distribution, in vivo antioxidant properties and colonic preneoplasia in rats. Nutr Res 19: 1383-1391
27. Kim L and Rao LG (2002) Effect of lycopene on prostate LNCaP cancer cells in culture. J Med Food 5: 181-187
28. Richards LR et al. (2003) The synergistic effect of conventional and sustained delivery of antioxidants on LNCaP prostate cancer cell line. Biomed Sci Instrum 39: 402-407
29. Karas M et al. (2000) Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells. Nutr Cancer 36: 101-111
30. Levy J et al. (1995) Lycopene is a more potent inhibitor of human cancer cell proliferation than either alpha-carotene or beta-carotene. Nutr Cancer 24: 257-266
31. Livny O et al. (2002) Lycopene inhibits proliferation and enhances gap-junction communication of KB-1 human oral tumor cells. J Nutr 132: 3754-3759
32. Amir H et al. (1999) Lycopene and 1,25-dihydroxyvitamin D3 cooperate in the inhibition of cell cycle progression and induction of differentiation in HL-60 leukemic cells. Nutr Cancer 33: 105-112
33. Herzog A et al. (2004) Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate. FASEB J Nov 15 [Epub ahead of print]
34. Chan JM et al. (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 536-563
35. Cohen P et al. (1993) Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 76: 1031-1035
36. Ho PJ and Baxter RC (1997) Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol (Oxf) 46: 333-342
37. Mantzoros CS et al. (1997) Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76: 1115-1118
38. Mucci LA et al. (2001) Are dietary influences on the risk of prostate cancer mediated through the insulin-like growth factor system? BJU Int 87: 814-820
39. Wolk A et al. (1998) Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 90: 911-915
40. Liu C et al. (2003) Lycopene supplementation inhibits lung squamous metaplasia and induces apoptosis via up-regulating insulin-like growth factor-binding protein 3 in cigarette smoke-exposed ferrets. Cancer Res 63: 3138-3144
41. Muller H et al. (1997) Induction of S-phase entry by E2F transcription factors depends on their nuclear localization. Mol Cell Biol 17: 5508-5520
42. Heber D and Lu QY (2002) Overview of mechanisms of action of lycopene. Exp Biol Med 227: 920-923
43. Ueda T et al. (2002) Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem. 277: 38087-39094
44. Jia L et al. (2004) Androgen receptor signaling: mechanism of interleukin-6 inhibition. Cancer Res 64: 2619-2626
45. Nelson WG et al. (2001) Preneoplastic prostate lesions: an opportunity for prostate cancer prevention. Ann N Y Acad Sci 952: 135-144
46. Kucuk OSF et al. (2001) Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev 10: 861-868
47. Matlaga BR et al. (2001) Response of hormone refractory prostate cancer to lycopene. J Urol 166: 613
48. Ansari MS and Gupta NP (2003) A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer. BJU Int 92: 375-378; discussion 378
49. Ansari MS and Gupta NP (2004) Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer. Urol Oncol 22: 415-420
50. Feifer AH et al. (2002) Analytical accuracy and reliability of commonly used nutritional supplements in prostate disease. J Urol 168: 150-154
51. Natural Health Products Directorate (2003) Natural Health Products Regulations [www.hc-sc.gc.ca/hpfb-dgpsa/nhpd-dpsn/nhp_regs_e.html] (accessed 24 November 2004)
52. US Food and Drug Administration (2003) Statement of John M Taylor, Associated Commissioner for Regulatory Affairs Food and Drug Administration, before the Committee on Commerce United States Senate, October 28, 2003 [www.fda.gov/ola/2003/dietarysupplements1028.html] (accessed 24 November 2004)